Proliferation News and Research

RSS

Research unmasks long sought stem cell origin of carcinoma

A constellation of different stem cell populations within our skin help it to cope with normal wear and tear. By constantly proliferating, the stem cells allow skin to replenish itself, allowing each cell to be replaced by a new one about once a month. But the normal cycle of division and death within one or more of these stem cell types can sometimes be derailed by genetic mishaps. Such events are believed to spawn carcinomas and other deadly skin cancers, which are the mostly frequently diagnosed cancers in the United States.

4 Feb 2011

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

The Damon Runyon Cancer Research Foundation announced that five scientists with novel approaches to fighting cancer have been named 2011 recipients of the Damon Runyon-Rachleff Innovation Award. The grant of $450,000 over three years is awarded each year to early career scientists whose projects have the potential to significantly impact the prevention, diagnosis and treatment of cancer.

2 Feb 2011

Study suggests human amniotic cells 'cross talk' with melatonin receptor MT1

Human amniotic epithelial cells, stem cells derived from human placenta left over from live births and generally discarded, proliferated and differentiated when they interacted with one kind of melatonin receptor, MT1. This potentially therapeutic response occurred when the stem cells were transplanted into laboratory test tube and animal models of stroke. The same cells did not perform similarly when interacting with melatonin receptor MT2.

2 Feb 2011

First commercially available full length human MTOR protein with superior biological activity released

OriGene Technologies, Inc., a gene-centric life sciences company, releases the first commercially available full length human MTOR protein with superior biological activity.

2 Feb 2011

EA sponsors research grant to investigate specific cancers and kinase mutations

Expression Analysis today announced a jointly sponsored research grant for up to eight American Cancer Society Grantees to investigate and draw parallels between specific cancers and recurring mutations in specific kinases, using targeted genome sequencing.

2 Feb 2011

Octreotide inhibits HepG2 proliferation, study confirms

Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world and is estimated to cause approximately half a million deaths annually. Undoubtedly, the best available treatment for all liver tumors is complete surgical resection. However, the synthetic somatostatin analogue octreotide has been found effective in inhibiting tumor growth in a variety of experimental models. It has been reported that octreotide inhibits the proliferation and induces apoptosis of different HCC cell lines in vitro.

1 Feb 2011

Study finds E2F5 transcription factor commonly overexpressed in primary human HCC

E2F5 is a member of the E2F transcription factor family, and plays a key role in cell growth and proliferation. Overexpression of E2F5 has been reported in various human cancers, but not in liver cancer, and its biological implication is largely unknown. It is not known whether E2F5 plays a tumor suppressor role or an oncogenic role.

1 Feb 2011

Cappella initiates multi-center Italian Sideguard open label clinical study

Cappella Medical Devices announces initiation of the multi-center Italian Sideguard® open label clinical study. The Principal Investigator (PI) of the study, Dr. Giuseppe Massimo Sangiorgi at the Policlinico di Modena - University of Modena and Reggio Emilia, in Modena, Italy stated, "The side branch ostium anatomy requires a unique technology solution to effectively manage and optimize treatment.

1 Feb 2011

Histamine can be an important molecule to develop new treatments for MS

If you think histamines are your nemesis during allergy season, here's something that might change your perspective. New research published in the Journal of Leukocyte Biology shows that histamine could be an important molecule to developing new treatments for multiple sclerosis.

1 Feb 2011

Antibiotic may help in development of new anti-cancer agents: Researchers

An antibiotic known for its immunosuppressive functions could also point the way to the development of new anti-cancer agents, researchers at the Indiana University School of Medicine have reported.

28 Jan 2011

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Plexxikon today announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis.

27 Jan 2011

Fibroblasts help 'recruit' immune cells for tumor growth

The most common connective tissue cell in animals is the fibroblast, which plays an important role in healing wounds. But Dr. Neta Erez of Tel Aviv University's Sackler Faculty of Medicine has now demonstrated that fibroblasts can also do a body great harm, helping to "recruit" immune cells for tumor growth.

27 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

DARPA grants $5.6 million to Dana-Farber to develop viable countermeasures against unknown pathogen

Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency and the Army Research Office to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens.

20 Jan 2011

Privatization of alcohol sales results in more alcohol-related death

Alcohol industry watchdog Marin Institute joined with Canadian and American researchers today to call attention to disturbing findings in a new study that should put the debate over privatizing alcohol sales in U.S. control states to rest once and for all.

19 Jan 2011

New project on developing countermeasures for natural and intentional exposure to disease pathogens

Researchers at Dana-Farber Cancer Institute have received a $5.6 million grant from the Defense Advanced Research Projects Agency (DARPA) and the Army Research Office (ARO) to develop transient immunity against known, unknown, naturally occurring, or engineered disease-causing pathogens. The ultimate goal is to develop a viable countermeasure to an unknown pathogen within seven days of receiving it in a laboratory.

19 Jan 2011

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

Researchers have identified how the hormones progesterone and estrogen interact to increase cell growth in normal mammary cells and mammary cancers, a novel finding that may explain why postmenopausal women receiving hormone replacement therapy with estrogen plus progestin are at increased risk of breast cancer.

19 Jan 2011

UQAM student identifies gene linked to B-cell acute lymphocytic leukemia

Cyndia Charfi, a Ph. D student in biology at Universit- du Qu-bec - Montr-al (UQAM), supported by her thesis supervisors, Professor -ric Rassart, and Adjunct Professor Elsy Edouard, UQAM, Department of Biological Sciences and BIOMED Research Centre, made a major breakthrough in research on B-cell acute lymphocytic leukemia, a disease that occurs most commonly in children.

19 Jan 2011

PAM50 test is now available to classify breast cancer subtypes

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced the availability of a new laboratory developed test designed to classify breast cancer into clinically significant molecular subtypes that are important for the management of the disease.

18 Jan 2011

Proliferation News and Research

Research unmasks long sought stem cell origin of carcinoma

Five young scientists receive Damon Runyon-Rachleff Innovation Award for cancer research

Study suggests human amniotic cells 'cross talk' with melatonin receptor MT1

First commercially available full length human MTOR protein with superior biological activity released

EA sponsors research grant to investigate specific cancers and kinase mutations

Octreotide inhibits HepG2 proliferation, study confirms

Study finds E2F5 transcription factor commonly overexpressed in primary human HCC

Cappella initiates multi-center Italian Sideguard open label clinical study

Histamine can be an important molecule to develop new treatments for MS

Antibiotic may help in development of new anti-cancer agents: Researchers

Plexxikon begins PLX5622 Phase 1 trial in patients with rheumatoid arthritis

Fibroblasts help 'recruit' immune cells for tumor growth

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

DARPA grants $5.6 million to Dana-Farber to develop viable countermeasures against unknown pathogen

Privatization of alcohol sales results in more alcohol-related death

New project on developing countermeasures for natural and intentional exposure to disease pathogens

Postmenopausal women receiving estrogen plus progestin at increased risk of breast cancer

UQAM student identifies gene linked to B-cell acute lymphocytic leukemia

PAM50 test is now available to classify breast cancer subtypes

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News